SCHEDULE: Vanguard Amends Royalty Pharma Stake to 2.52%
Beneficial Ownership Report (Schedule 13G Amendment)
The Vanguard Group has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 2.52% in Royalty Pharma PLC as of September 30, 2025.
Summary
- The Vanguard Group reported beneficial ownership of 10,936,538 shares of Royalty Pharma PLC common stock.
- This represents 2.52% of the class of securities.
- Vanguard holds sole dispositive power over 7,867,386 shares and shared dispositive power over 3,069,152 shares.
- Vanguard holds shared voting power over 2,227,676 shares and no sole voting power.
- This is Amendment No. 3 to a Schedule 13G.
- Vanguard certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Royalty Pharma PLC.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership by an institutional investor and does not contain information that would inherently be positive or negative for the issuer's operational performance or future prospects.
Positives
- NA (This filing primarily reports beneficial ownership, not operational performance or positive developments for the issuer.)
Negatives
- NA (This filing primarily reports beneficial ownership, not operational performance or negative developments for the issuer.)
Risks
- NA (This filing primarily reports beneficial ownership and does not detail risks related to the issuer's business operations.)
Future Outlook
NA (Schedule 13G does not contain forward-looking statements or guidance from the issuer.)
Management Comments
- NA (This filing reports the ownership of The Vanguard Group, not statements from Royalty Pharma PLC's management.)
Industry Context
This Schedule 13G filing indicates a significant institutional investment by The Vanguard Group, a major investment adviser, in Royalty Pharma PLC. Such filings are standard disclosures for large asset managers holding stakes in publicly traded companies, reflecting their portfolio management activities rather than a strategic corporate action by the issuer.
Comparison to Industry Standards
- NA (This filing is a disclosure of beneficial ownership by an investment adviser, not a performance report that can be compared to industry benchmarks.)
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | NA |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | NA | NA | NA |
Legal Proceedings
- NA (This filing does not mention any litigation or regulatory matters.)
Related Party Transactions
- NA (This filing does not disclose any related party dealings.)
Stakeholder Impact
- Shareholders of Royalty Pharma PLC are informed of The Vanguard Group's current beneficial ownership stake, providing transparency regarding institutional holdings.
- The filing confirms that Vanguard's stake is held in the ordinary course of business and not for control purposes, which may reassure other investors about the stability of the company's governance.
Next Steps
- NA (The filing itself does not outline future actions or milestones for Royalty Pharma PLC or Vanguard beyond the reporting requirement.)
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which requires filing of this statement |
| 10/30/2025 | Signature date of the filing |
Keywords
Royalty Pharma PLC, Vanguard Group, Schedule 13G, beneficial ownership, common stock, investment adviser, institutional ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.